Clinical trials: Neoplasia Prostate
Prostate Cancer
Prostate SABR With Intra-Prostatic SABR Boost
Stereotactic Ablative Radiation (SABR/SBRT) will be prescribed to a dose of 35 Gy in 5 fractions, once weekly to prostate with a simultaneous intra-prostatic boost to the MR detected nodule up to 50Gy.
- Trial name
- NCT04212715
- Testing
- Pelvic SABR with intra-prostatic SABR
- Where
- Saudi Arabia
- Volunteers
- 30 people
- Sponsor
- King Saud University
Breast Cancer, Non-small Cell Lung Cancer
Study to Evaluate the Safety of Nanoxel M Inj.
Study to evaluate the safety of Nanoxel M inj. administration in patients.
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer
- Trial name
- NCT04066335
- Where
- South Korea
- Volunteers
- 1,498 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Breast Cancer, Metastatic Castration-resistant Prostate Carcinoma
Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity
Docetaxel is used as a first line anti-cancer drug in the treatment of several cancers, mainly breast- and metastatic castration-resistant prostate carcinoma.
- Trial name
- LEANDOC (NCT01621425)
- Testing
- Lean body mass, Total body weight, bloodsampling
- Where
- 2 sites in Netherlands
- Volunteers
- 25 people
- Sponsor
- Radboud University Medical Center
Erectile Dysfunction, Prostate Cancer
Intra-operative Neuromodulation of the Pelvic Plexus
The purpose of this study is to evaluate the feasibility of electrical stimulation of nerves responsible for erectile function to evoke penile erection after surgery to remove the prostate (prostatectomy).
- Trial name
- NCT03425240
- Testing
- Nerve Stimulation
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- Laikο General Hospital, Athens
Prostate Cancer
A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
The primary objective of the study is to determine the response rate to TPI 287 in patients with metastatic, hormone-refractory prostate cancer who have had one prior taxane regimen.
- Trial name
- NCT00479635
- Testing
- TPI 287
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Cortice Biosciences, Inc.
Prostatic Neoplasms
Effect of Casodex on Tumour Hypoxia - Prostate Cancer
Prostate cancers, in common with many other tumours, are often hypoxic; that is, they have low levels of oxygen. It is thought that tumour hypoxia may hasten the progression of cancers and make them more resistant to treatment.
- Trial name
- NCT00188708
- Testing
- hypoxia measurement
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy
This is a single arm, open label study of up to 20 patients with prostate cancer scheduled for prostatectomy at the NIH Clinical Center.
- Trial name
- NCT01279785
- Testing
- 123I-MIP-1072
- Where
- United States
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Prostate Adenocarcinoma, Obesity, Morbid
Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer
The standard of care for obese men starting Androgen deprivation therapy (ADT) is physician based dietary and exercise counseling. Interventions to lessen the harmful effects of ADT are needed yet have been limited.
- Trial name
- BASH-PC (NCT04331717)
- Testing
- Bead Block 300-500 um, Weight Management, Lupron
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Malignant Glioma, Hepatocellular Carcinoma
Early-Phase Safety of Proton Therapy Equipment
The main purpose of this study is to collect the safety data of Sumitomo Heavy Industries' proton therapy equipment for the treatment of solid cancer patients in Linkou Chang Gung Memorial Hospital, including the patients'…
- Conditions
- Malignant Glioma, Hepatocellular Carcinoma, Head and Neck Malignant Tumor, Prostate Cancer
- Trial name
- NCT02315989
- Testing
- proton therapy
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- Chang Gung Memorial Hospital
NSCLC, SCLC
Study of Oral MRT-2359 in Selected Cancer Patients
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer…
- Conditions
- NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL
- Trial name
- NCT05546268
- Testing
- Oral MRT-2359
- Where
- 17 sites in United States
- Volunteers
- 174 people
- Sponsor
- Monte Rosa Therapeutics, Inc
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.
- Trial name
- OPTIMAS (NCT07216248)
- Testing
- relugolix + ARPI, Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI, relugolix or androgen deprivation therapy (ADT) + ARPI
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Utah
Prostatic Cancer
Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer
The purpose of this study is to determine whether quinacrine is effective in the treatment of Androgen-Independent Prostate Cancer.
- Trial name
- NCT00417274
- Testing
- Quinacrine
- Volunteers
- 31 people
- Sponsor
- Cleveland BioLabs
Prostate Cancer
Race-related Alternative Splicing: Novel Targets in Prostate Cancer
Data from evaluating prostate cancer (PCa) biopsy tissue from AA and white patients has led to the discovery of alternative splicing as a novel molecular mechanism underlying more aggressive PCa in AA men.
- Trial name
- PCaP splicing (NCT03424213)
- Testing
- No interventions - retrospective data collection
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Duke University
Metastatic Prostate Cancer
Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.
Prostate cancer is the most frequently diagnosed non-skin cancer, and the second leading cause of men cancer death in the United States. Hormonal therapy remains a first-line treatment for metastatic prostate cancer.
- Trial name
- ABIDO (NCT02036060)
- Testing
- docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d, docetaxel 75 mg/m2 + prednisone 10 mg/d
- Where
- 17 sites in Spain
- Volunteers
- 119 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Prostate Carcinoma
Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer
This trial studies how well magnetic resonance whole body diffusion-weighted imaging works in finding cancer that has spread to the bone or lymph nodes (metastasis) in participants with high-risk prostate cancer.
- Trial name
- NCT03085043
- Testing
- Bone Scan, Computed Tomography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Quality of Life in Prostate Cancer Patients
Recording cancer data in cancer registries is essential for producing reliable population-based data for service planning, monitoring and evaluation.
- Trial name
- QoLProstateMQ (NCT04357925)
- Where
- Martinique
- Volunteers
- 304 people
- Sponsor
- University Hospital Center of Martinique
Prostate Cancer
Music Listening as a Postanesthesia Care Unit (PACU) Nursing Intervention
A randomized comparison clinical trial will be conducted in laparoscopic radical prostatectomy patients in the Weinberg PACU at the Johns Hopkins Hospital.
- Trial name
- NCT04596917
- Testing
- Preferred music listening, Relaxation breathing narrative over hypnotic music listening
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Recurrent Prostate Cancer After Surgery
This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.
There is significant, proven use of radiation for recurrent prostate cancer after surgical resection. This treatment typically is delivered over seven and a half weeks of daily treatments, presenting a burden to patients and the…
- Trial name
- DASBRT-RPC (NCT05946824)
- Testing
- Daily-adaptive Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Prostate Cancer
Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer
This study will evaluate the use of magnetic resonance imaging (MRI) for guiding placement of hollow needles into the prostate gland for delivering internal radiation therapy to patients with prostate cancer.
- Trial name
- NCT00039624
- Testing
- Brachytherapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other…
- Conditions
- Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT03678025
- Testing
- Abiraterone, Bicalutamide, Degarelix
- Where
- 338 sites in United States, Chile and 3 more
- Volunteers
- 1,273 people
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.